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Multimodal Nonopioid Pain Protocol Provides
Equivalent Pain Versus Opioid Control Following
Meniscus Surgery: A Prospective Randomized
Controlled Trial
Touﬁc R. Jildeh, Kelechi R. Okoroha, M.D., Noah Kuhlmann, B.S., Austin Cross, B.S.,
Muhammad J. Abbas, B.S., and Vasilios Moutzouros, M.D.

Purpose: To assess the effectiveness of a nonopioid pain regimen in controlling postoperative pain as compared with a
traditional opioid pain control following primary meniscectomy or meniscal repair. Methods: Ninety-nine patients undergoing primary meniscectomy or meniscal repair were assessed for participation. A prospective randomized control trial
was performed in accordance with the Consolidated Standards of Reporting Trials 2010 statement. The 2 arms of the study
included a multimodal nonopioid analgesic protocol and a standard opioid regimen with a primary outcome of postoperative pain level (visual analog scale) for the ﬁrst 10 days postoperatively. Secondary outcomes included patientreported outcomes, complications, and patient satisfaction. Randomization was achieved using a random-number
generator. Patients were not blinded. Data collection was done by a blinded observer. Results: Eleven patients did not
meet the inclusion criteria, and 27 declined participation. A total of 61 patients were analyzed with 30 randomized to the
opioid regimen and 31 randomized to the nonopioid regimen. Patients receiving the nonopioid regimen demonstrated
noninferior visual analog scale scores compared with patients who received opioid pain medication (P > .05). No signiﬁcant differences were found in preoperative (opioid: 58.9  7.0; nonopioid: 58.2  5.5, P ¼ .724) or postoperative
(opioid: 59.8  6.5; nonopioid: 54.9  7.1, P ¼ .064) Patient-Reported Outcomes Measurement and Information System
Pain Interference Short Form scores. No difference was found in recorded side effects between both groups at any given
time point: constipation, nausea, diarrhea, upset stomach, and drowsiness (P > .05). Conclusions: This study found that
a multimodal nonopioid pain protocol provided equivalent pain control and patient outcomes following primary meniscus
surgery while having an equivalent side effect proﬁle. All patients reported satisfaction with their pain management
without requiring emergency opioid analgesia. Level of Evidence: Level I, prospective randomized controlled trial.

ith the declaration of pain as the ﬁfth vital sign in
patients, there has been increased attention on
treating acute and chronic pain. Increased opioid prescriptions have added to the opioid abundance and
dependence in the United States. Currently, Americans
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ﬁnd themselves in an opioid epidemic, and in 2017, the
opioid epidemic was declared a national emergency in
the United States.1 Opioid prescriptions increased from
76 million in 1990 to a peak of 255 million in 2012,
with a 6-fold increased death toll between 1990 and
2017.2,3 The US population accounts for 4.6% of the
world population but represents approximately 80% of
global opioid consumption.4 In a recent study, musculoskeletal pathology ranked as the second leading
category associated with an initial opioid prescription,
which in turn led to sustained opioid use.5 Postoperative pain has proven to be one of the most challenging aspects of patient care for orthopaedic surgeons,
and surgeons are uniquely positioned to exert a positive
effect on the current epidemic.
Arthroscopic meniscus surgery is the most common orthopaedic surgery, and meniscectomy and meniscal repair
represent prime targets for reduction of postoperative
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opioid use.6 Attempts have been made to reduce the
overall opioid burden for these surgeries. Most notably,
Daniels et al.7 found that most patients undergoing
arthroscopic partial meniscectomy achieve satisfactory
pain control with nonopioid pain management. In addition, many studies have employed multimodal analgesia
to decrease postoperative opioid burden following many
surgical procedures.8-10 The usage of multimodal analgesia
allows for effective pain control through targeting pain
receptors at multiple points of the nociceptive pathway.
Recently, a multimodal nonopioid pain regimen suggested
adequate pain control following common sports procedures with few to no breakthrough opioid medication, but
no multimodal pain regimen has been able to eliminate
the need for opioid pain medication.11
The purpose of this randomized controlled trial was to
assess the effectiveness of a nonopioid pain regimen in
controlling postoperative pain as compared with a
traditional opioid pain control following primary
meniscectomy or meniscal repair. We hypothesized
that our nonopioid protocol would demonstrate no
signiﬁcant difference in postoperative pain control
compared with a standard opioid regimen. Our secondary hypothesis was that patients in the nonopioid
cohort will experience a reduced side effect proﬁle
when compared with patients in the opioid cohort.

Methods
This study was designed as a randomized controlled trial
with 2-week follow-up. The Consolidated Standards of
Reporting Trials statement was followed to conduct this
prospective, observer-blinded, randomized controlled
trial12 (Fig 1). The hypothesis was formulated prior to
collection of data. The study was reviewed and approved
by our institutional review board (IRB No. 12318) and
was registered at ClinicalTrials.gov (NCT03820193).
Between February 2019 and January 2020, 91 patients who presented to 2 fellowship-trained sports
surgeons and were scheduled for primary arthroscopic
meniscectomy or meniscal repair were screened for
study eligibility. The inclusion criteria consisted of patients aged older than 16 years and patients undergoing
primary arthroscopic meniscectomy or meniscal repair.
Patients were excluded if they had a signiﬁcant history
of substance abuse, peptic ulcer disease, recent or current pregnancy, intolerance or allergy to any study
medication, renal impairment or dysfunction, samejoint surgery for any reason within the previous year,
use of blood thinner medication, gastrointestinal
bleeding, use of opioid medication within 3 months of
surgery, or if they were undergoing revision surgery.
Studies have shown that patients using opioids preoperatively demonstrated sustained opioid use postoperatively, and opioid-naive patients were selected to
limit confounders.13-15 All concomitant cartilage procedures were recorded (Table 1).

A secure computer database was used to store data of
patients included in the study. Following surgical discussion, patients consented for participation were
randomly assigned to either an opioid or a nonopioid
pain regimen with a 1:1 allocation ratio using adaptive
randomization computer software (MD Anderson
Cancer Center, Houston, TX). One week before surgical
intervention, surgeons were notiﬁed by secure e-mail
of the patient’s group designation for the upcoming
week by the project coordinator. The study did not
require physician blinding due to patient outcomes
being self-reported. Research staff was not involved
with the care of the patients and performed enrollment
and data collection. Meniscus repair was performed
through an all-inside technique.
Intervention
Preoperatively, all patients received onetime doses of
the following medications: gabapentin 300 mg, tramadol
50 mg, acetaminophen 975 mg, and celecoxib 400 mg. In
addition, an intravenous dose of dexamethasone 8 mg
was administrated preoperatively. An intraoperative
local inﬁltration consisting of 150 mg (30 mL) 0.50%
ropivacaine, 1 mg (1 mL) epinephrine, and 30 mg (1 mL)
ketorolac was evenly injected in 2-mL increments along
the subcutaneous incision at portal sites prior to closure
using a 20-mL syringe with a 22-gauge, 1-inch needle.
Patients in the nonopioid group received a novel nonopioid multimodal analgesic protocol described previously
in the literature.11 The protocol consisted of multiple
nonopioid medications used to alter postoperative pain
using various mechanisms. Acetaminophen and nonsteroidal anti-inﬂammatory drugs (NSAIDs) (ketorolac and
meloxicam) were used to target the pain cascade and
postoperative inﬂammation, respectively. Gabapentin
was used to address neuropathic pain and diazepam to
control muscle cramps and spasm. Medication dosage and
frequency are described in Table 2.
Patients enlisted in the opioid group were prescribed
40 pills of 5 mg hydrocodone/325 mg acetaminophen
and instructed to take 1 to 2 pills orally every 4 to 6
hours as needed (PRN) for moderate to severe postoperative pain.
Patients were then discharged home on the day of
surgery per their group designation pain protocol. All
patients were encouraged to contact the on-call physician if pain control was unbearable or they were experiencing any side effects or complications. Patients were
also given instructional pamphlets on the effects of opioids, ways to effectively manage pain postoperatively,
and pain treatment goals following surgery.
Outcomes
All data collection was performed by observers who
were blinded to group randomization. Prior to surgery,
patients were instructed to complete a Patient-Reported
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Fig 1. Consolidated Standards of
Reporting Trials ﬂow diagram.
Patients were excluded if they had
a signiﬁcant history of substance
abuse, peptic ulcer disease, recent
or current pregnancy, intolerance
or allergy to any study medication,
renal impairment or dysfunction,
same-joint surgery for any reason
within the previous year, use of
blood thinner medication, gastrointestinal bleeding, use of opioid
medication within 3 months of
surgery, or if they were undergoing revision surgery.

Outcomes Measurement and Information System Pain
Interference Short Form (PROMIS PI-SF) questionnaire
at the preoperative assessment. Following surgery, a
mobile messaging-based outcomes collection software
(Mosio, Seattle, WA) was used to collect patient data
postoperatively. The software allows patients to submit
responses to surveys using numerical text message responses and allows for quick and efﬁcient collection.
Surveys were sent to patients 3 times a day for 10 days
postoperatively.
Each day using the mobile-messaging application,
patients were asked to report their current pain level
using an 11-point ordinal scale (visual analog scale
[VAS]) 3 times daily: in the morning (9 AM), afternoon
(1 PM), and evening (7 PM). Each evening, patients were
then asked to report medical side effects, as well as how
many opioid pills were taken in the last 24 hours (if
applicable). Opioid consumption was converted to
morphine milligram equivalents (MME). At the ﬁrst
postoperative visit (7-10 days), patients also completed
the PROMIS PI-SF questionnaires.

The following variables were abstracted from medical
records: demographic data (age, sex, body mass index
[BMI], and history of diagnosed psychiatric condition),
smoking status, anxiety/depression status, workers
compensation status, and preoperative opioid chronicity.
Statistical Analysis
The primary outcome of this study was an average
daily pain difference of 13 mm on the VAS score, as a
previous study demonstrated this difference represents
the minimum clinically important difference of the
VAS score.12 Prestudy power analysis, with a power of
80% (b level ¼ .80, a level ¼ .05) revealed that a
minimum of 25 patients per group (n ¼ 50) was
necessary to properly evaluate the primary hypothesis.
All continuous data were described using means,
standard deviations, medians, minimums, and maximums. Categorical data were presented using counts
and column percentages. Continuous data were
compared between groups using the Wilcoxon ranksum test, and categorical data were compared using
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Table 1. Demographic Characteristics of Patients Prescribed
Opioid and Nonopioid Protocols for Postoperative Analgesia
Characteristic
Age, mean  SD, y
Sex
Male
Female
Race
White
African American
Hispanic
Asian
Other
Unknown
Body mass index,
mean  SD, kg/m2
Smoker
Yes
No
Depression
Yes
No
Meniscus repair
Yes
No
Meniscus excision
Yes
No
Chondroplasty
Yes
No
Loose body removal
Yes
No
Microfracture
Yes
No

Opioid (n ¼ 30)
48.8  14.1

Nonopioid
(n ¼ 31)
41.3  16.4

22 (73)
8 (27)

22 (71)
9 (29)

17 (57)
6 (20)
1 (3)
1 (3)
3 (10)
2 (7)
30.2  6.3

16 (52)
5 (16)
0 (0)
2 (6)
5 (16)
3 (10)
28.5  5.0

P Value
.059
.837

.830

.233
.613

7 (23)
23 (77)

9 (29)
22 (71)

3 (10)
27 (90)

2 (6)
29 (94)

1 (3)
29 (97)

1 (3)
30 (97)

29 (97)
1 (3)

30 (97)
1 (3)

20 (67)
10 (33)

19 (61)
12 (39)

0 (0)
30 (100)

2 (6)
29 (94)

0 (0)
30 (100)

1 (3)
30 (97)

.671

1.000

1.000

.662

.492

1.000

Values are presented as number (%) unless otherwise indicated.
Bold values denote statistical signiﬁcance (P < .05).

c2 or Fisher exact text. Univariate Poisson regression
models were used to compare VAS and number of
hydrocodone pills between groups, with results

displayed using least squares means and 95% conﬁdence intervals. Repeated-measures analyses were
performed using mixed models and included the effects of time, group, and the interaction between time
and group. Models were then adjusted for using
speciﬁed variables. Predicted means resulting from the
adjusted models were plotted for the outcome variables. Spearman correlation coefﬁcient was used to
describe the relationship between the number of
hydrocodone pills and pain score. Statistical signiﬁcance was set at P < .05. All analyses were performed
using SAS 9.4 (SAS Institute, Cary, NC).

Results
Patient Demographics
Ninety-nine consecutive patients with the primary
diagnosis of meniscal tear were assessed for participation
in the study. Twenty-seven declined participation and 11
were also excluded in the study due to signiﬁcant history
of substance abuse, peptic ulcer disease, renal impairment, or dysfunction. A total of 61 patients were
included in the study for analysis. Thirty patients were
randomized to receive opioid analgesia, and 31 patients
were randomized to receive nonopioid analgesia. The
entire study population had a mean age of 45.0  15.7
years and an average BMI of 29.35 kg/m2, with males
constituting 72% of all participants. No patients were
workers compensation claims. No signiﬁcant differences
exist between any of the demographic variables between
the 2 cohorts. All demographic characteristics can be
visualized in Table 2. Of the 30 patients in the opioid
cohort, 43.3% of patients reported discontinuing opioid
usage prior to postoperative day 10.
Postoperative Analgesia: Opioid vs Nonopioid
Regimens
There were no signiﬁcant differences in the reported
VAS pain scores between the opioid and nonopioid

Table 2. Multimodal Nonopioid Pain Regimen
Morning
- Ketorolac 10 mg
- Gabapentin 300 mg
- Diazepam 5 mg
- Acetaminophen 1,000 mg

Postoperative Days 1-5
Noon
Afternoon
- Ketorolac 10 mg
- Ketorolac 10 mg
- Gabapentin 300 mg
- Gabapentin 300mg
- Diazepam 5 mg
- Diazepam 5 mg
- Acetaminophen 1,000 mg
- Acetaminophen 1,000 mg

Evening
- Ketorolac 10 mg
- Diazepam 5 mg

Postoperative Days 6-14
Morning
- Meloxicam 7.5 mg
- Diazepam 5 mg
- Acetaminophen 1,000 mg

Afternoon
- Meloxicam 7.5 mg
- Diazepam 5 mg
- Acetaminophen 1,000 mg

Evening
- Diazepam 5 mg
- Acetaminophen 1,000 mg

Preoperative per os (PO) regimen: PO celecoxib 400 mg, acetaminophen 975 mg, gabapentin 300 mg, tramadol 50 mg, dexamethasone 8 mg
intravenous. Intraoperative local inﬁltration analgesia: 150 mg (30 mL) ropivacaine, 30 mg (1 mL) ketorolac, and 1 mg (1 mL) epinephrine.
Gabapentin weaning began on postoperative day 6 in the following manner: 300 mg in the morning and 300 mg in the evening on days 6 to 7,
300 mg in the morning on days 8 to 9, and discontinuation on day 10.
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Fig 2. Mean visual analog scale
(VAS) pain score of the opioid
and nonopioid groups for the ﬁrst
10 postoperative days. Patients in
the nonopioid group reported
noninferior
pain
control
compared with the opioid group.
Bold values denote statistical signiﬁcance (P < .05).

cohorts (Fig 2). When accounting for confounding
variables with measured mixed models, there were no
signiﬁcant differences found in preoperative (opioid:
58.9  7.0; nonopioid: 58.2  5.5, P ¼ .724) or postoperative (opioid: 59.8  6.5; nonopioid: 54.9  7.1,
P ¼ .064) PROMIS-PI scores (Fig 3). Mean pain levels
were predicted using VAS scores and repeatedmeasures mixed models and showed no signiﬁcant
difference between the opioid and nonopioid groups
(Fig 4). Measured mixed models demonstrated that
opioid consumption was highest in the ﬁrst 3 postoperative days (POD 1: 1.6  1.4 pills, 8.2  7.2 MME;
POD 2: 1.8  1.9 pills, 9.1  9.7 MME; and POD 3:
1.6  1.9 pills, 7.8  9.5 MME) and lowest on postoperative days 6, 7, and 10 (POD 6: 0.9  1.7 pills, 4.3 
8.3 MME; POD 7: 0.8  1.8, 3.8  8.9 MME; POD 10:
0.9  1.7, 4.5  8.3 MME) among the group receiving
opioid analgesia (Fig 5).
A Pearson correlation did not ﬁnd any signiﬁcant
ﬁndings between age, sex, BMI, race, workers
compensation, presence of meniscus repair, loose body
removal, or microfracture and VAS pain score (Table 3).
Pearson correlations did return signiﬁcance between
presence of a chondroplasty and VAS pain score on
postoperative days 8 and 9. A Pearson correlation failed
to show signiﬁcance between presence of meniscus
repair, loose body removal, chondroplasty, or microfracture and MME at every postoperative day (P > .05).
Patient-Reported Adverse Events
There were no signiﬁcant differences between the 2
groups in the number of days patients reported each
adverse event, including constipation (P ¼ .124),
nausea (P ¼ .979), diarrhea (P ¼ .464), upset stomach
(P ¼ .174), drowsiness (P ¼ .572), and dizziness

(P ¼ .217) (Table 4). The number of days patients reported no adverse events was also nonsigniﬁcant between the groups (opioid: 5.3  3.8; nonopioid: 5.8 
3.4, P ¼ .798). The most commonly reported adverse
events in both groups were constipation (opioid: 1.9 
2.9; nonopioid: 0.9  2.0) and drowsiness (opioid:
2.5  3.6; nonopioid: 1.0  1.6). Neither group had any
intraoperative or postoperative complications, such as
venous thromboembolism, infection, or reoperation.
Patients in the nonopioid group reported zero complications in compliance with the medication protocol, no
additional need for emergent opioid analgesia, and a
100% satisfaction with pain control. Patients in the
opioid group did not require additional opioid analgesic
medication.

Discussion
The current study found that pain control and patient
satisfaction were no different in patients undergoing
meniscal surgery who had either a multimodial nonopioid pain regimen or an opioid pain regimen postoperatively. Pain following meniscus surgery was able
to be effectively managed without opioids while
maintaining an equivalent side effect proﬁle. Due to the
addictive nature of opioids and the dramatic increase in
opioid-related deaths in the past 20 years,16 this study
suggests that using a nonopioid multimodal pain control regimen following a primary meniscectomy or
meniscal repair is a viable alternative for managing
postoperative pain.
There is a paucity of literature evaluating a completely
opioid-free pain regimen prospectively in meniscal surgery. Research supporting single-agent alternatives to
opioids has offered promise for the elimination of
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Fig 3. Predicted Patient-Reported
Outcomes Measurement and Information System Pain Interference Short Form (PROMIS PI-SF)
scores for opioid and nonopioid
groups. Nonsigniﬁcant differences
exist for PROMIS-PI SF scores
between the 2 groups while controlling for age, sex, body mass
index, depression, and anxiety.

narcotic use in the postoperative window. Carrier et al.17
examined patient satisfaction with NSAID use following
partial meniscectomy. They examined 34 patients who
were prescribed ibuprofen 800 mg postoperatively with
a 2-week follow-up and found that 82% of patients did

not use any opioids and reported that they were sufﬁciently satisﬁed with pain control achieved. In a prospective observational study, Pham et al.18 examined the
postoperative pain control of 77 patients following
meniscectomy with oxycodone/acetaminophen alone or

Fig 4. Predicted mean hourly
pain levels for opioid and nonopioid groups. Nonsigniﬁcant difference exists for pain levels
between the 2 groups while controlling for age, sex, body mass
index, smoking status, depression,
and anxiety. VAS, visual analog
scale.
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Fig 5. Predicted mean morphine
milligram equivalents (MME) for
opioid pain control group. Controlling for the effects of age, sex,
body mass index, anxiety, and
depression, no signiﬁcant effects
were found.

ibuprofen plus oxycodone/acetaminophen for breakthrough pain. The authors found that patients who
received NSAIDs and opioids for breakthrough pain had
no signiﬁcant difference in pain level and satisfaction
compared with patients who received opioids alone
(VAS score 1.8 vs 1.5, P ¼ .64, NSAID vs opioid).
Furthermore, Pham et al.18 found in their study that
53% of patients in the opioid group independently chose
to forego their opioid medication and used NSAIDs and
acetaminophen instead, suggesting that opioids are being overprescribed following meniscal surgery. Drez
et al.19 evaluated 52 patients’ pain levels 6 hours after
surgery following arthroscopy or arthroscopic meniscectomy in a multicenter, double-blinded randomized,
parallel trial. Patients were randomized and received

either naproxen sodium or propoxyphene napsylate
with acetaminophen (PN/A), and they found that patients taking naproxen had a more rapid decline in the
pain intensity differences in the ﬁrst hour postoperatively as compared with the PN/A group (23.9 vs
10.8, P ¼ .017, NS vs PN/A), advocating for the use of
NSAIDs after meniscus surgery. Last, Moutzouros et al.11
performed a case series of 141 patients (49 arthroscopic
partial meniscectomy) and examined the postoperative
pain control following a multimodal pain regimen. The
authors found that 1 week following meniscus surgery,
patients reported a mean VAS level of 2.6  2.3, and
45% of all patients required no breakthrough opioids
and achieved satisfactory pain control. The present study
evaluated patients in a prospective randomized fashion

Table 3. Pearson Correlation Coefﬁcients Between VAS Pain and Intraoperative Procedures
POD
1
2
3
4
5
6
7
8
9
10

Meniscus Repair
e0.2111
e0.06015
e0.02549
e0.02674
e0.05458
e0.08687
e0.14849
e0.16219
e0.16004
e0.17877

P Value
.8762
.6688
.8548
.8507
.6979
.5486
.3034
.2707
.272
.2456

Chondroplasty
e0.11175
0.01823
0.07465
0.07446
0.0506
0.11821
0.22141
0.31038
0.28769
0.20995

P Value
.4079
.8969
.5916
.5998
.719
.4136
.1223
.0318
.045
.1714

Loose Body Removal
0.12385
e0.02843
e0.07351
e0.00743
0
0.02896
e0.04923
e0.06655
e0.0108
e0.08541

P Value
.3587
.8399
.5973
.9583
1
.8418
.7342
.6531
.4895
.5815

Microfracture
e0.16716
e0.16716
e0.1748
e0.16747
e0.15288
e0.15537
e0.15949
e0.1536
e0.15323
e0.17387

P Value
.2139
.2139
.2061
.2354
.2745
.2813
.2686
.2973
.2932
.259

Bold values denote statistical signiﬁcance (P < .05). Chondroplasty on POD 8 and 9 was found to have a positive correlation with VAS pain.
POD, postoperative day; VAS, visual analog scale.
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Table 4. Reported Adverse Events in Opioid and Nonopioid
Pain Groups
Adverse Event
Constipation, d
Nausea, d
Diarrhea, d
Upset stomach, d
Drowsiness, d
Dizziness, d

Opioid (n ¼ 30)
1.9  2.9
0.3  0.6
0.1  0.5
0.4  0.7
2.5  3.6
0.0  0.2

Nonopioid (n ¼ 31)
0.9  2.0
0.4  1.2
0.0  0.2
0.2  0.5
1.0  1.6
0.4  1.3

P Value
.124
.979
.464
.174
.572
.217

Values are presented as mean  SD.

and found no difference in pain score between patients
receiving a nonopioid and an opioid pain protocol. This
suggests a nonopioid pain regimen can be effective in
decreasing narcotic consumption following meniscal
surgery in a safe and effective manner. It should be
noted that while concerns exist regarding the use of
NSAIDs and bone healing, 2 meta-analyses by Kurmis
et al.20 and Marquez-Lara et al.21 have established there
is no high-quality literature supporting NSAID inhibition
of tissue healing in the clinical setting.
When managing postoperative pain, it is critical to
maximize therapeutic effects while striving to minimize
any adverse effects of the drugs that can negatively affect
patient experience and their hospital stay. In a prior case
series, Moutzouros et al.11 found that 53.6% of patients
reported no adverse effects of their pain regimen, and
23.5% of patients reported they were experiencing
drowsiness. The most common reported adverse events
in both groups were constipation (opioid: 1.9  2.9;
nonopioid: 0.9  2.0) and drowsiness (opioid: 2.5  3.6;
nonopioid: 1.0  1.6). In the present study, adverse effects were tracked in real time, and patients were asked
to report side effects each day. Our study found no signiﬁcant difference in constipation, nausea, diarrhea,
drowsiness, or dizziness between the opioid and nonopioid protocols. Of note, postoperative narcotic usage is
widely known to induce constipation, with up to 60% of
patients reporting this effect.11 Interestingly, the present
study demonstrated a nonsigniﬁcant decrease in reported constipation postoperatively in the nonopioid
cohort when compared with the opioid cohort (0.9 vs 1.9
days, respectively). A future investigation into the
incorporation of a bowel regimen could help determine if
postoperative constipation can be further minimized
following meniscal surgery for patients receiving a
nonopioid pain regimen. The incidence of reported
constipation in the nonopioid cohort can likely be
attributed to the synergistic effect of gabapentin and
diazepam, which have both been demonstrated to cause
constipation in patients.22,23 These ﬁndings suggest an
equivalent side effect proﬁle for the nonopioid regimen
with a diminished risk of opioid dependence.
In the initial study evaluating opioid use after meniscus
surgery, Moutzouros et al.11 sent patients home with an

adjunct rescue opioid (oxycodone 5 mg), and patients
reported a VAS score of 2.6  2.3 while taking 1.6  3.4
oxycodone pills (5.2  11.3 morphine equivalents). In
their cohort, patients undergoing meniscus surgery had
signiﬁcantly better pain control than those undergoing
rotator cuff repair, labrum surgery, or anterior cruciate
ligament reconstruction. In the present cohort, patients
reported a VAS score of 1.3  1.3 at an equivalent time
(POD 10) without consuming any opioids whatsoever,
which was improved from the opioid analgesic cohort
(2.3  1.7), although this ﬁnding was not statistically
signiﬁcant. This disparity may be attributed to the
multimodal nature of the pain protocol, where multiple
steps of the nociceptive pathway are targeted, as
compared with opioid analgesia where pain is blocked at
essentially a singular point. In a comparative study of
medial meniscal repair, partial meniscectomy, and intact
meniscus following concomitant anterior cruciate ligament reconstruction, Aglietti et al.24 found that at an
average follow-up of 55 months, patients who underwent partial meniscectomies had a signiﬁcant increase in
pain experienced when compared with other groups.
Given these ﬁndings, in combination with the present
study, there is suggestion that pain after meniscus surgery is exceptionally low, particularly when considering
that there is no insult to the bony anatomy and that
patient’s perception of pain may be dependent on how
much meniscus is damaged and/or removed. This may
allow for alteration of the pain protocol and deescalation of the multimodal protocol for relatively
small meniscal lesions, but more work must be done in
meniscus surgery and postoperative pain dynamics.
Limitations
This study is not without limitations. The ﬁrst limitation
is that it was not possible to double blind this study as all
patients were informed of their current postoperative
treatment. This could have introduced bias-reported pain
scores, as could patients opting to not take opioid medication because of the known side effect proﬁle. The second limitation of this study was our inability to measure
patient compliance with prescribed medication. This
could have introduced bias-reported pain scores, as could
patients opting to not take opioid medication because of
the known side effect proﬁle. Third, this study was only
powered to identify a signiﬁcant difference in VAS scores
between cohorts and was not powered to detect differences in adverse drug effects, function, mental status,
postoperative complications, or long-term pain and
disability past 10 days postoperatively. A larger sample
size would have been required in order to perform a
subgroup analysis of psychosocial variables that could
have affected pain perception and opioid intake. Twentyseven patients declined to participate in the study, primarily due to preexisting preferences for postoperative
pain control; this represents a potential confounder due to
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the effect of subject bias. Two patients were found to
require meniscal repair following diagnostic arthroscopy,
and it was not possible to exclude these patients due to the
stated aim of the study. These patients may potentially
confound the level of reported pain control as meniscal
repairs may present with higher levels of postoperative
pain.

Conclusions
This study found that a multimodal nonopioid pain
protocol provided equivalent pain control and patient
outcomes following primary meniscus surgery while
having an equivalent side effect proﬁle. All patients
reported satisfaction with their pain management
without requiring emergency opioid analgesia.
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